IP Library Granted Patent US 9,149,487
Granted Patent B2
US 9,149,487 · App. 14/279,232 · Granted Oct 6, 2015

Compositions for oral adminstration of zoledronic acid or related compounds for treating Paget's disease of bone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,149,487
App. No.
14/279,232
Granted
Oct 6, 2015
Kind
B2
Abstract

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.

Claims (18)

1. A method of treating arthritis pain comprising administering an oral dosage form containing zoledronic acid to a human being in need thereof, wherein the human being receives about 40 mg to about 300 mg of zoledronic acid per month, and wherein the human being experiences pain relief that lasts for a duration of at least 48 hours, and the human being receives zoledronic acid no more often than once daily.

2. The method of claim 1 , wherein the human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered.

3. The method of claim 1 , wherein zoledronic acid is administered for only 1 to 3 months.

4. The method of claim 1 , wherein the human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour after the zoledronic acid is administered.

5. The method of claim 1 , wherein the human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours after the zoledronic acid is administered.

6. The method of claim 1 , wherein the human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour before the zoledronic acid is administered.

7. The method of claim 1 , wherein the human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours before the zoledronic acid is administered.

8. The method of claim 1 , wherein the zoledronic acid is administered weekly.

9. The method of claim 1 , wherein the zoledronic acid is administered weekly for 1 or 2 months.

10. The method of claim 1 , wherein the zoledronic acid is administered once a month, or less frequently.

11. The method of claim 1 , wherein the zoledronic acid is administered 2 to 5 times in a month.

12. The method of claim 1 , wherein the zoledronic acid is administered daily.

13. The method of claim 1 , wherein the human being has an age of at least 10 years.

14. The method of claim 1 , wherein the human being has an age of about 20 years to about 95 years.

15. The method of claim 1 , wherein the arthritis affects, a knee, an elbow, a wrist, a shoulder, or a hip.

16. The method of claim 1 , wherein the arthritis affects a knee.

17. The method of claim 1 , wherein the human being has suffered from the arthritis for at least 6 months.

18. The method of claim 1 , wherein the human being has suffered from the arthritis for at least 1 month.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2016
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 039065/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 032907/0514 →